Dan Roden, MD, FAHA
Vanderbilt University Medical Center
Dan Roden, MD, is Professor of Medicine, Pharmacology, and Biomedical Informatics and Senior Vice-President for Personalized Medicine at Vanderbilt University Medical Center. His research program studies how genetic variation affects human disease susceptibility, with a focus on pharmacogenetics, and on genetic determinants of abnormal heart rhythms, especially those induced by drugs. After serving as chief of Clinical Pharmacology for 12 years, he was tasked in 2006 with leading Vanderbilt’s efforts in Personalized Medicine. Under his leadership, Vanderbilt has become internationally recognized for cutting edge programs in this area, including the large (250,000 sample) biobank BioVU and the EHR-based preemptive pharmacogenetic program PREDICT. He served as Principal Investigator for the Vanderbilt sites of the Pharmacogenomics Research Network (2001-2021), and currently serves as PI for the Vanderbilt site of the Electronic Medical Records and Genomics (eMERGE) Network (2007-2025), and the All of Us Data and Research Center.
Dr. Roden has received the American Society for Clinical Pharmacology and Therapeutics’ Leon Goldberg Young Investigator Award, Rawls Palmer Progress in Science Award, and the Oscar Hunter Career Award; the Distinguished Scientist Award from the Heart Rhythm Society; the Distinguished Scientist Award and the inaugural Functional Genomics and Translational Biology Medal of Honor from the AHA; the Alumnus Lifetime Achievement Award and the Louis and Artur Lucian Award in Cardiovascular Research from McGill; and the Jay and Jeanie Schottenstein prize in Cardiovascular Sciences from the Ohio State University. He has been elected to membership in ASCI and AAP, and fellowship in AAAS.